AbbVie announces new business, Allergan Aesthetics

AbbVie announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and the proposed leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition.

Allergan Aesthetics will operate as a new global dedicated business with its own research and development function under the AbbVie umbrella and will include leading aesthetic products including, BOTOX Cosmetic, the JUVEDERM collection of dermal fillers and COOLSCULPTING body contouring, among others.

This global business, located in Irvine, California, will be led by Carrie Strom, currently Senior Vice President, U.S. Medical Aesthetics, Allergan. Upon completion of the Allergan acquisition, Ms. Strom will be named Senior Vice President, AbbVie and President, Global Allergan Aesthetics.  She will oversee the worldwide operations, along with an experienced team of current Allergan leaders, and report directly to Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie.  

The Eye Care and Specialty businesses – including BOTOX Therapeutics, Central Nervous System, Women’s Health and Gastrointestinal Diseases – will be integrated into the existing AbbVie organisation. Several Allergan leaders have accepted leadership positions in the future company across these franchises.

Differentiate your business, build thought leadership and boost lead generation by reaching the Australian Pharma, MedTech and Biotech industry professionals. Health Industry Hub offers unique media solutions to vendors and suppliers servicing the industry. Contact us.

“We are enthusiastic about the potential of the new AbbVie and continue to make significant progress on completing our acquisition of Allergan,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “The announcement marks an important step forward in our plans to create the integrated global company.  We are fortunate to have a leadership team with a deep breadth of both industry and company experience and we are excited to welcome the new Allergan leaders to our Company.”

The more than $3 billion in annual sales from Botox (onabotulinumtoxinA) were a chief draw for AbbVie, as were eyecare and specialty drugs that could help AbbVie sustain itself through expected losses due to future competition to its top-seller Humira (adalimumab). 

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

You may also like 91% of clinicians use reprints to improve patient care